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Abstract
Background: The best treatment approach for ST-segment elevation myocardial infarction (STEMI) is prompt
primary percutaneous coronary intervention (PCI). However, some patients show ST elevation on electrocardiography
(ECG), but do not have myocardial infarction. We sought to identify the frequency of and to develop a prediction model
for false-positive STEMI.
Methods: This study was conducted in the emergency departments (EDs) of two hospitals using the same
critical pathway (CP) protocol to treat STEMI patients with primary PCI. The prediction model was developed
in a derivation cohort and validated in internal and external validation cohorts.
Results: Of the CP-activated patients, those for whom ST elevation did not meet the ECG criteria were excluded.
Among the patients with appropriate ECG patterns, the incidence of false-positive STEMI in the entire cohort was 16.3%.
Independent predictors extracted from the derivation cohort for false-positive STEMI were age < 65 years (odds ratio
[OR], 2.54; 95% confidence interval [CI], 1.35–4.89), no chest pain (OR, 12.04; 95% CI, 5.92–25.63), atypical chest pain (OR,
7.40; 95% CI, 3.27–17.14), no reciprocal change (OR, 4.80; 95% CI, 2.54–9.51), and concave-morphology ST elevation (OR,
14.54; 95% CI, 6.87–34.37). Based on the regression coefficients, we established a simplified risk score. In the internal and
external validation cohorts, the areas under the receiver operating characteristic curves for our risk score were 0.
839 (95% CI, 0.724–0.954) and 0.820 (95% CI, 0.727–0.913), respectively; the positive predictive values were 40.
9% and 22.0%, respectively; and the negative predictive values were 94.9% and 96.7%, respectively.
Discussion: Our prediction model would help them make rapid decisions with better rationale.
Conclusion: We devised a model to predict false-positive STEMI. Larger-scale validation studies are needed to
validate our model, and a prospective study to determine whether this model is effective in reducing improper primary
PCI in actual clinical practice should be performed.
Keywords: ST-segment elevation myocardial infarction, Percutaneous coronary intervention, Electrocardiography, Risk
score, Predictive model
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Background
Primary percutaneous coronary intervention (PCI) is a
standardized treatment approach for ST-segment elevation
myocardial infarction (STEMI). Timely reperfusion ther-
apy is especially crucial for salvaging reversible infarcted
lesions and minimizing myocardial damage. Therefore, the
American College of Cardiology/American Heart Associ-
ation (ACC/AHA) guidelines recommend that therapy be
conducted within 90 min of door-to-balloon time [1].
Multidisciplinary cooperation is necessary to achieve this
target time; therefore, many emergency departments (EDs)
use the critical pathway (CP) protocol [2, 3]. The protocol
provides a guide for each department to simplify the
decision-making process and enable prompt action. The
door-to-balloon time for STEMI patients has been short-
ened in the past several years [4–6]. However, some pa-
tients show ST elevation on electrocardiography (ECG),
but do not have myocardial infarction (MI). This is called
false-positive STEMI. As the door-to-balloon time of
STEMI patients has been reduced, the number of patients
who are falsely diagnosed with STEMI in whom unneces-
sary emergency coronary angiography (CAG) is performed
has increased [7].
Several studies have been conducted to date on false-
positive STEMI patients. Emergency CAG performed in
patients with false-positive STEMI is not uncommon, with
reported rates varying between 7.5% and 36.0% [8–14].
CAG is an invasive procedure that increases risks for pa-
tients and medical expenditures. The procedure can affect
patient safety because other tests and treatments are de-
layed, and the diagnosis cannot be made in a timely man-
ner [7, 15]. Recently, several attempts have been made to
reduce unnecessary CAG by investigating predictors of
falsely diagnosing a patient with STEMI [8, 9, 16]. One
study has suggested the use of a prediction model for
false-positive STEMI [16]. However, the decision about
whether to perform emergency procedures in patients
with suspected STEMI still depends on the competence of
individual physicians, and the false diagnosis of STEMI
continues to occur.
The objectives of our study were to determine the fre-
quency of false-positive STEMI diagnosis in our system,
to develop a prediction model for false-positive STEMI,
and to validate this model internally and externally.
Methods
Study setting and participants
This was a retrospective, observational study of pro-
spectively collected data in two urban tertiary teaching
hospitals. The derivation and internal validation cohorts
were derived from hospital A, and the external valid-
ation cohort was obtained from hospital B. Both hospi-
tals are located in Seoul, the capital city of Korea, and
both have level 2 EDs. Hospital A is located in the
northwest of the city, which is responsible for treating
emergency patients from three districts with a popula-
tion of 1.13 million, and 80,000 patients visit the ED
every year. Hospital B, which is an affiliated hospital of
A, is located in the southeast, covering two districts
comprising 920,000 people, with 50,000 annual ED visits.
The two hospitals have 24 and 7 catheterization rooms,
respectively, and perform approximately 4000 and 1500
CAGs per year, respectively. Our research was approved
by each hospital’s institutional review board, and patient
consent was waived owing to the retrospective nature of
the study. The methodological quality was assessed by 3
authors (M.J. Kim, Y.H. Roh, and Y.S. Park) using the
QUADAS criteria [17].
Patients who were examined between January 2010
and December 2013 in the ED of hospital A were ran-
domly divided into the derivation (75%) and internal val-
idation (25%) cohorts. Data on the external validation
cohort were obtained between January 2010 and Decem-
ber 2012 from hospital B. In both hospitals, the same CP
protocol was used for patients with STEMI; when
STEMI was suspected based on clinical symptoms and
ECG findings, the emergency physician activated the CP.
Then, the ED nurse, diagnostic laboratory, cardiologist,
catheterization room staff, and transport staff were mo-
bilized, and the cardiologist performed primary PCI. We
investigated patients older than 18 years who underwent
the CP in the derivation, internal validation, and external
validation cohorts. The CP protocol included new-onset
left bundle branch block (LBBB) as well as ST-segment
elevation. Our inclusion criterion was the only CP acti-
vation for patients with ST-segment elevation. In some
patients, the CP was activated based on ST-segment ele-
vation, but ST elevation was not clear on ECG. The ex-
clusion criterion was no definite ST-segment elevation
on ECG.
Data collection and definitions
We determined ST-segment elevation according to the cri-
teria in the ACC/AHA guideline. The criteria are a J-point
elevation in two or more contiguous leads with a cut-off
value of ≥0.1 mV (1 mm) in all leads other than V2 and
V3, for which the following cut-off values were applied:
0.2 mV (2 mm) in men ≥40 years old, 0.25 mV (2.5 mm)
in men <40 years old, or 0.15 mV (1.5 mm) in women [18].
False-positive STEMI was defined as a lack of a culprit
artery observed on CAG. A culprit lesion was identified
on CAG if there was total or subtotal occlusion or stenosis
>70% (>50% in the left main coronary artery) with a visible
thrombus or other features that suggested acute plaque
rupture in the coronary artery corresponding to ST-
segment elevation on ECG. However, some patients did
not undergo CAG for various reasons, such as an absence
of consent to undergo the procedure, uncertainty of the
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clinical benefit for patients with terminal illness, or those
with cardiac arrest prior to coronary intervention. We ap-
plied a clinical scenario to determine whether these pa-
tients had false-positive STEMI. The clinical scenario was:
1) the patient was diagnosed with another disease in
which the ECG finding was clearly explicable before dis-
charge; and 2) the patient was not diagnosed with another
disease, but did not show elevated levels of cardiac bio-
markers or receive any treatments for myocardial infarc-
tion (MI) during hospitalization. The first biomarker assay
result was determined as positive when the troponin I
value was ≥0.2 ng/mL (reference interval: <0.2 ng/mL) or
the creatine kinase-MB value was ≥7% of the creatine
kinase value.
We extracted data from the patients’ electronic med-
ical records that included ECG and angiographic results.
The patients’ baseline characteristics, underlying disease,
cardiovascular risk factors, typical chest pain, onset time
of symptoms, radiating pain, method of ED arrival,
hemodynamic instability in the ED, and ECG patterns
were investigated. Each ECG lead was reviewed for the
presence of ST elevation, height and shape of ST eleva-
tion, and the presence of reciprocal changes. According
to the involved leads, the ST elevation locations were
classified as anterior, inferior, posterolateral, or diffuse.
The anterior area was defined as an ST elevation in two
or more adjacent leads among V1 to V4. The inferior
area was defined as an ST-segment elevation in two or
more adjacent leads among II, III, and aVF. The lateral
area was defined as an ST-segment elevation in two or
more adjacent leads among I, aVL, V5, and V6. The pos-
terior area was defined as an ST-segment of 0.05 mV or
greater in leads V7 to V9 but 0.1 mV or greater in men
younger than 40 years. Posterolateral wall MI was de-
fined as ST-segment elevation in two or more adjacent
leads near the posterior and lateral walls. A diffuse loca-
tion of ST elevation referred to ST elevation that was
distributed in more than one coronary artery area. We
analysed the maximal height of the ST elevation, which
was the greatest height in all leads with ST elevation.
For the shape of the ST elevation, we determined
whether the morphology was concave based on the line
from the J point to the end of the ST segment [10]. ST
depression was recognized as a reciprocal change if it
was in the anterior or lateral areas for inferior ST eleva-
tion, in the inferior area for anterior or lateral ST eleva-
tion, or in the anterior area for posterior ST elevation
[19]. We also checked for the presence of a Q wave and
left ventricular hypertrophy. Left ventricular hypertrophy
was defined using an ECG computer algorithm.
Statistical analysis
We built a predictive model for false-positive STEMI
using data from the derivation cohort. A univariate
analysis was performed using independent t-tests for
continuous variables and χ2 tests for categorical vari-
ables. To determine the independent predictors for
false-positive STEMI, a multivariable logistic regression
analysis was conducted. The determination of clinically
significant factors was based on previous studies and fac-
tors associated with false-positive STEMI on the univari-
ate analysis (p < 0.1). Logistic regression coefficients
were used to generate a risk score for false-positive
STEMI. To facilitate clinical application of this score,
the coefficient of each variable was divided by the lowest
beta values, multiplied by a constant, and rounded to
the nearest integer. In the derivation dataset, calibration
was assessed using the Hosmer-Lemeshow goodness-of-
fit test for the simplified score model. The final risk
score was validated in the internal and external valid-
ation cohorts. The predictability of the risk score for
false-positive STEMI was assessed by calculating the
area under the receiver operating characteristic
(AUROC) curve. We employed three cohorts to test the
diagnostic characteristics of the cut-off point for the
final model based on standard validation measures: sen-
sitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV). The cut-off value was
chosen for our predictive model to maximize the You-
den Index (defined as sensitivity + specificity of 1) [20].
All p-values were two-sided, and 95% confidence inter-
vals (CI) were calculated for odds ratios (ORs). All ana-
lyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC, USA) and R version 3.3.2 (The R
Foundation for Statistical Computing, Vienna, Austria).
Results
Cohort analysis
In the derivation and internal validation cohorts (hos-
pital A), the CP was activated in 1002 patients during
the study period (Fig. 1). Nine patients with ECG loss
and two patients who died before further evaluation
were excluded. The CP was activated due to new-onset
LBBB in 54 (5.4%) patients. Of the 948 (94.6%) patients
whose protocol was activated by ST elevation, 331
(34.9%) did not meet the criteria for ST-segment eleva-
tion. Although the ST-segment elevation was not clear,
77 (23.3%) patients underwent emergent CAG, and 23
patients were diagnosed with non-STEMI (NSTEMI).
Among the 331 patients, 109 (32.9%) patients with
NSTEMI, including 86 patients who were not treated
with primary PCI but were diagnosed with NSTEMI,
followed by no diagnosis (43, 13.1%), structural/valvular
heart disease (37, 11.1%), and primary rhythm disturb-
ance (35, 10.6%). Finally, 617 patients with appropriate
ST-segment elevation were included in the study. We
applied a clinical scenario to determine false-positive
STEMI in 102 (16.5%) patients who did not undergo
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primary PCI. The overall frequency of false-positive
STEMI was 112 (18.2%). In the external validation co-
hort (hospital B), 204 patients were included, and 22
(10.8%) patients were falsely diagnosed with STEMI. The
overall incidence of false-positive STEMI for both hospi-
tals was 16.3%.
The baseline characteristics of the derivation and the
internal and external validation cohorts are shown in
Table 1. The external validation cohort had a greater
proportion of patients who were younger than 65 years
of age compared with those in the derivation cohort
(51.8% vs. 63.7%, p = 0.004), and more patients smoked
(45.8% vs. 56.9%, p = 0.008). There were more cases of
ambulance arrival (46.0% vs. 54.4%, p = 0.042), and
fewer Q waves were observed on ECG (4.3% vs. 0.5%,
p = 0.007) in the external validation cohort compared
with that in the derivation cohort. The frequency of
false-positive STEMI was also lower in the external val-
idation cohort (18.2% vs. 10.8%, p = 0.015) than in the
derivation cohort.
Model development
The clinical characteristics of the STEMI and false-
positive STEMI patients were compared in the deriv-
ation cohort (Table 2). In the univariate analysis, patients
who were falsely diagnosed with STEMI were younger
than the STEMI patients (age < 65 years, 47.3% vs.
72.2%, p < 0.001) and were more likely to be male
(79.2% vs. 88.9%, p = 0.038). The prevalence of diabetes
mellitus, hypertension, and hypercholesterolemia was
higher in patients with STEMI than in falsely diagnosed
patients, but a history of variant angina was more com-
mon in false-positive STEMI patients (0.5% vs. 5.6%,
p = 0.004) than in STEMI patients. More patients with
STEMI complained of typical chest pain (78.7% vs.
35.6%, p < 0.001) and radiating pain (30.9% vs. 15.6%,
p = 0.004) than did false-positive STEMI patients. Posi-
tive baseline biomarkers were observed more often in
STEMI than in false-positive STEMI patients (45.5% vs.
16.7%, p < 0.001). The ST-segment elevation in false-
positive STEMI patients tended to be located in the
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Fig. 1 Flow chart showing the critical pathway activation protocol and study enrolment. The derivation and internal validation cohorts were
extracted from hospital A; the external validation cohort was extracted from hospital B. CP, critical pathway; STE, ST elevation; LBBB, left bundle
branch block; ECG, electrocardiography; STEMI, ST-segment elevation myocardial infarction
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Table 1 Characteristics of the patients in the derivation and internal/external validation cohorts
Derivation (n = 494) Internal validation (n = 123) P1-value External validation (n = 204) P2-value
Age < 65 years 256 (51.8) 68 (55.3) 0.491 130 (63.7) 0.004
Male, n (%) 400 (81.0) 93 (75.6) 0.184 166 (81.4) 0.902
BMI, mean ± SD 23.7 mea 23.9 mea 0.509 24.99mea <0.001
Diabetes mellitus, n (%) 162 (32.8) 34 (27.6) 0.272 65 (31.9) 0.811
Hypertension, n (%) 256 (51.8) 69 (56.1) 0.395 101 (49.5) 0.578
Chronic renal failure, n (%) 23 (4.7) 7 (5.7) 0.633 6 (2.9) 0.302
Hypercholesterolemia, n (%) 68 (13.8) 14 (11.4) 0.486 38 (18.6) 0.104
Current smoking, n (%) 226 (45.8) 49 (39.8) 0.238 116 (56.9) 0.008
Previous event, n (%)
Stroke 21 (4.3) 9 (7.3) 0.157 7 (3.4) 0.616
Variant angina 7 (1.4) 1 (0.8) 1.000 2 (1.0) 1.000
Unstable angina 30 (6.1) 7 (5.7) 0.873 7 (3.4) 0.157
Myocardial infarction 45 (9.1) 8 (6.5) 0.356 6 (2.9) 0.004
CAD 82 (16.6) 13 (10.6) 0.097 16 (7.8) 0.002
Heart failure 16 (3.2) 0 0.052 3 (1.5) 0.305
Previous PCI 73 (14.8) 15 (12.2) 0.464 16 (7.8) 0.012
Previous CABG 11 (2.2) 1 (0.8) 0.476 1 (0.5) 0.196
Family history of CAD, n (%) 31 (6.3) 5 (4.1) 0.518 16 (7.8) 0.452
Chest pain, n (%)
Typical 350 (70.9) 84 (68.3) 0.850 151 (74.0) 0.175
Atypical 57 (11.5) 15 (12.2) 14 (6.9)
No chest pain 87 (17.6) 24 (19.5) 39 (19.1)
Other symptom, n (%) 215 (43.5) 48 (39.0) 0.367 65 (31.9) 0.004
Radiating pain, n (%) 139 (28.1) 27 (22.0) 0.166 59 (28.9) 0.834
Symptom onset to arrival, n (%)
≤ 6 h 383 (77.5) 79 (64.2) 0.003 169 (82.8) 0.064
6-24 h 63 (12.8) 30 (24.4) 26 (12.7)
> 24 h 48 (9.7) 14 (11.4) 9 (4.4)
Ambulance arrival, n (%) 227 (46.0) 40 (32.5) 0.007 111 (54.4) 0.042
Hemodynamic instability, n (%) 88 (17.8) 20 (16.3) 0.685 35 (17.2) 0.836
Positive baseline biomarker, n (%) 199 (40.3) 58 (47.2) 0.167 63 (30.9) 0.020
Location of STE, n (%)
Anterior 209 (42.3) 57 (46.3) 0.253 82 (40.2) 0.474
Inferior 190 (38.5) 40 (32.5) 75 (36.8)
Posterolateral 19 (3.8) 9 (7.3) 6 (2.9)
Diffuse 76 (15.4) 17 (13.8) 41 (20.1)
Height of maximal STE (mm) 3.1±2.0 3.2 ± 2.1 0.581 3.5 ± 2.1 0.049
Number of leads with STE 3.2 ± 1.2 3.1 ± 1.1 0.505 3.5 ± 1.3 0.007
No reciprocal change, n (%) 252 (51.0) 62 (50.4) 0.904 126 (61.8) 0.010
Concave morphology of STE, n (%) 243 (49.2) 51 (41.5) 0.125 94 (46.1) 0.454
Q wave, n (%) 21 (4.3) 4 (3.3) 0.800 1 (0.5) 0.007
LVH, n (%) 70 (14.2) 14 (11.4) 0.420 25 (12.3) 0.502
False-positive STEMI, n (%) 90 (18.2) 22 (17.9) 0.932 22 (10.8) 0.015
P1 denotes the P-value that compares the derivation and internal validation cohorts, and P2 denotes the P-value that compares the derivation and external
validation cohorts. SD standard deviation, BMI body mass index, CADcoronary artery disease, PCI percutaneous coronary intervention, CABG coronary artery
bypass graft, STE ST elevation, LVH left ventricular hypertrophy, STEMI ST-segment elevation myocardial infarction, SD standard deviation
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Table 2 Comparison between the STEMI and false-positive STEMI patients in the derivation cohort
STEMI (n = 404) False-positive STEMI (n = 90) OR (95% CI) P-value
Age < 65 years 191 (47.3) 65 (72.2) 2.90 (1.76–4.79) <0.001
Male, n (%) 320 (79.2) 80 (88.9) 2.10 (1.04–4.23) 0.038
BMI, mean ± SD 23.8 ± 3.6 23.1 ± 3.5 0.95 (0.89–1.01) 0.121
Diabetes mellitus, n (%) 142 (35.1) 20 (22.2) 0.53 (0.31–0.90) 0.020
Hypertension, n (%) 220 (54.5) 36 (40.0) 0.56 (0.35–0.89) 0.014
Chronic renal failure, n (%) 17 (4.2) 6 (6.7) 1.63 (0.62–4.25) 0.321
Hypercholesterolemia, n (%) 63 (15.6) 5 (5.6) 0.32 (0.12–0.82) 0.017
Current smoking, n (%) 193 (47.8) 33 (36.7) 0.63 (0.40–1.01) 0.057
Previous event, n (%)
Stroke 20 (5.0) 1 (1.1) 0.22 (0.03–1.63) 0.137
Variant angina 2 (0.5) 5 (5.6) 11.82 (2.26–61.93) 0.004
Unstable angina 25 (6.2) 5 (5.6) 0.89 (0.33–2.40) 0.820
Myocardial infarction 37 (9.2) 8 (8.9) 0.97 (0.44–2.16) 0.937
CAD 68 (16.8) 14 (15.6) 0.91 (0.49–1.70) 0.769
Heart failure 13 (3.2) 3 (3.3) 1.04 (0.29–3.72) 0.955
Previous PCI 60 (14.9) 13 (14.4) 0.97 (0.51–1.85) 0.922
Previous CABG 9 (2.2) 2 (2.2) 1.00 (0.21–4.70) 0.998
Family history of CAD, n (%) 29 (7.2) 2 (2.2) 0.29 (0.07–1.26) 0.098
Chest pain, n (%)
Typical 318 (78.7) 32 (35.6) 1 (reference) <0.001
Atypical 37 (9.2) 20 (22.2) 5.37 (2.79–10.33)
No chest pain 49 (12.1) 38 (42.2) 7.71 (4.41–13.47)
Other symptom, n (%) 160 (39.6) 55 (61.1) 2.40 (1.50–3.83) <0.001
Radiating pain, n (%) 125 (30.9) 14 (15.6) 0.41 (0.22–0.76) 0.004
Symptom onset to arrival, n (%)
≤ 6 h 319 (79.0) 64 (71.1) 1 (reference) 0.186
6-24 h 50 (12.4) 13 (14.4) 1.30 (0.67–2.52)
> 24 h 35 (8.7) 13 (14.4) 1.85 (0.93–3.69)
Ambulance arrival, n (%) 181 (44.8) 46 (51.1) 1.29 (0.82–2.04) 0.278
Hemodynamic instability, n (%) 73 (18.1) 15 (16.7) 0.91 (0.49–1.67) 0.753
Positive baseline biomarker, n (%) 184 (45.5) 15 (16.7) 0.24 (0.13–0.43) <0.001
Location of STE, n (%)
Anterior 155 (38.4) 54 (60.6) 1 (reference)
Inferior 165 (40.8) 25 (27.8) 0.44 (0.26–0.73) 0.002
Posterolateral 14 (3.5) 5 (5.6) 1.03 (0.35–2.98) 0.964
Diffuse 70 (17.3) 6 (6.7) 0.25 (0.10–0.60) 0.002
Height of maximal STE (mm) 3.3 ± 2.1 2.4 ± 1.1 0.72 (0.61–0.85) <0.001
Number of leads with STE 3.3 ± 1.2 2.8 ± 1.0 0.61 (0.47–0.81) <0.001
No reciprocal change, n (%) 181 (44.8) 71 (78.9) 4.60 (2.68–7.92) <0.001
Concave morphology of STE, n (%) 162 (40.1) 81 (90.0) 13.4 (6.56–27.53) <0.001
Q wave, n (%) 21 (5.2) 0 <0.01 (<0.01- > 99.99) 0.971
LVH, n (%) 52 (12.9) 18 (20.0) 1.69 (0.94–3.06) 0.082
STEMI ST-segment elevation myocardial infarction, OR odds ratio, CI confidence interval, SD standard deviation, BMI body mass index, CAD coronary artery disease,
PCI percutaneous coronary intervention, CABG coronary artery bypass graft, STE ST elevation, LVH left ventricular hypertrophy
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anterior area compared with that in STEMI patients
(38.4% vs. 60.6%, p < 0.001). In addition, the height of
the ST elevation was lower and the number of leads with
ST elevation was less in false-positive STEMI patients
than in STEMI patients. Reciprocal change was more
common in STEMI patients than in false-positive
STEMI patients (44.8% vs. 78.9%, p < 0.001). More pa-
tients with falsely diagnosed STEMI had concave ST ele-
vation shapes than did STEMI patients (40.1% vs. 90.0%,
p < 0.001).
To identify predictors for false-positive STEMI, a mul-
tivariable logistic regression analysis was performed
(Table 3). The independent predictors were age < 65 years
(OR, 2.54; 95% CI, 1.35–4.89; p = 0.004), absence of
chest pain (OR, 12.04; 95% CI, 5.92–25.63; p < 0.001) or
atypical chest pain (OR, 7.40; 95% CI, 3.27–17.14;
p < 0.001), no reciprocal change (OR, 4.80; 95% CI,
2.54–9.51; p < 0.001), and concave-morphology ST ele-
vation (OR, 14.54; 95% CI, 6.87–34.37; p < 0.001). Based
on the regression coefficients, we established a risk score
system to predict false-positive STEMI by assigning a
simplified score to these factors (Table 3). The range of
the total risk score was between 0 and 8 points. The p-
value for the Hosmer-Lemeshow test was 0.574, suggest-
ing that our model was well calibrated.
Validation of the model
The ability of our final model to predict false-positive
STEMI in the derivation cohort was 0.893 (95% CI
0.856–0.930), as estimated by the AUROC curve (Fig. 2).
In the internal and external validation cohorts, the sim-
plified risk score showed good discrimination for false-
positive STEMI, with AUROCs of 0.839 (95% CI 0.724–
0.954) and 0.820 (95% CI 0.727–0.913), respectively.
Based on the Youden Index, a cut-off point of ≥2.5 was
used to predict false-positive STEMI in the derivation
cohort. Based on this cut-off value, the sensitivity and
specificity of false-positive STEMI were 83.3% and
76.2%, respectively, the PPV was 43.9%, and the NPV
was 93.4% (Table 4). In the internal and external valid-
ation cohorts, the sensitivity was 81.8% and 81.8%, re-
spectively, and the specificity was 74.3% and 64.8%,
respectively. The PPV was 40.9% and 22.0%, respectively,
and the NPV was 94.9% and 96.7%, respectively.
Aetiologies of false-positive STEMI
The aetiology of the 134 cases of false-positive STEMI
in all cohorts was classified. The distribution of the final
diagnosis is shown in Table 5. Coronary spasm (28.4%)
was the most common cause of false-positive STEMI.
Other common aetiologies included primary rhythm dis-
turbance (19.4%) and structural/valvular heart disease
(12.7%). Causes (12.7%) other than cardiovascular events
were subarachnoid cerebral haemorrhage, massive
gastrointestinal bleeding, and metabolic causes. Among
the total population, 15.7% were not diagnosed with any
disease. In 134 patients with false-positive STEMI, emer-
gency CAG was performed in half (67 patients), and cor-
onary spasm (26, 38.8%) was the most common
diagnosis, followed by no diagnosis (12, 17.9%), and pri-
mary rhythm disturbance (10, 14.9%).
Discussion
In this study, the overall incidence of false-positive
STEMI was 16.3%. Age, characteristics of chest pain, re-
ciprocal change on ECG, and concave morphology of ST
elevation were independent predictors for false-positive
STEMI and were included in the final prediction model.
Our model was presented as a risk score that ranged
from 0 to 8 points and showed a good level of accuracy
for false-positive STEMI prediction, with an AUROC of
0.8 or higher. When the cut-off value of 2.5 was applied,
high NPV and low PPV were obtained.
As noted, the overall incidence of false-positive STEMI
was 16.3%, but there was a gap between the two hospitals
(18.2% vs. 10.8%). Both hospitals used the same protocol,
and the differences may have been due to differences in
patient demographics; the patients in hospital B were
younger than those in hospital A. The prevalence of false-
positive STEMI has broadly been reported to be between
7.5% and 36.0% [8–14]. Not only patient characteristics
but also study design can affect the incidence of falsely di-
agnosed STEMI. Studies that only included patients who
received primary PCI showed a lower incidence of false-
positive STEMI (7.5%–11.0%) [8, 10, 11, 16]. When calcu-
lating the incidence only in patients with primary PCI in
our study, the incidence of false-positive STEMI was 9.4%.
Table 3 Multivariable predictors of false-positive STEMI in the
derivation cohort and simplified risk score
Variables Beta OR (95% CI) P value Risk score
Age
≥ 65 years 1 (reference) 0
< 65 years 0.93 2.54 (1.35–4.89) 0.004 1
Chest pain
Typical 1 (reference) 0
Atypical 2.00 7.40 (3.27–17.14) <0.001 2
No 2.49 12.04 (5.92–25.63) <0.001 2.5
Reciprocal change
Yes 1 (reference) 0
No 1.57 4.80 (2.54–9.51) <0.001 1.5
Concave morphology of STE
Yes 2.68 14.54 (6.87–34.37) <0.001 3
No 1 (reference) 0
STEMI ST-segment elevation myocardial infarction, OR odds ratio, CI confidence
interval, STE ST elevation
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However, in a study that included all patients in whom the
CP was activated for STEMI, the incidence increased to
36.0% [13]. The authors of that study applied a clinical
scenario to patients who did not receive primary PCI for
the judgment of false-positive STEMI, similar to our
study. Most patients presenting with the typical character-
istics of STEMI received primary PCI, and the proportion
of false-positive STEMI patients in clinical scenario-
applied patients was naturally higher (59.8% in our study)
than that for primary PCI patients. Thus, the prevalence
of false-positive STEMI may have been underestimated in
studies that included only patients who underwent pri-
mary PCI.
Over-activation of the CP for patients with a high sen-
sitivity for disease detection is reasonable to a certain
degree, because not missing real STEMI is more import-
ant than false activation. Mixon et al. also noted this
problem, stating that the rate of improper ECG patterns
was 12.8% among patients who underwent CP activation
in an investigation of the appropriateness of using ECG
to evaluate STEMI [14]. In studies that included CP-
activated cases as a denominator regardless of the appro-
priateness of ECG, the rate of false-positive STEMI was
25.6%–28.4%, higher than the actual value [14, 21]. In
our study, we endeavoured to exclude these “false alarm”
cases to clarify the precise study population. However,
surprisingly, there were more patients than expected
with ECG results that did not meet the ST-elevation cri-
teria (331, 34.9%). This high incidence of false alarm
could be influenced by government policy. In 2007, the
Korean government began to grade hospitals according
to the proportion of patients who successfully received
primary PCI within 90 min of arrival, and the grade in-
fluences the hospital’s funding for STEMI patients.
Therefore, physicians focus on activating the CP rather
than on false alarms when they encounter unclear clin-
ical situations in which STEMI is suspected.
Patients with new-onset LBBB were not included in
our investigation. These patients tend to show a greater
proportion of false-positive STEMI than ST-elevation
on ECG, and Qiangjun et al. suggested a guideline
using the Sgarbossa score to prevent unnecessary cor-
onary intervention in patients with new-onset LBBB
[22]. The ACC/AHA guideline insists that patients with
new or presumably new LBBB should no longer be
treated as STEMI-equivalent [23]. Thus, we devised our
prediction model only for patients with ST-segment
elevation, and if patients with new-onset LBBB were in-
cluded, the incidence of false-positive STEMI would
increase.
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Table 4 Diagnostic characteristics of the simplified risk score cut-off points in the three cohorts
Derivation Internal validation External validation
Sensitivity % (95% CI) 83.3 (75.6–97.0) 81.8 (65.7–97.9) 81.8 (65.7–97.9)
Specificity % (95% CI) 76.2 (72.1–80.4) 74.3 (65.7–82.8) 64.8 (57.9–71.8)
Positive predictive value % (95% CI) 43.9 (36.4–51.3) 40.9 (26.4–55.4) 22.0 (13.0–30.9)
Negative predictive value % (95% CI) 93.4 (93.1–97.7) 94.9 (90.1–99.8) 96.7 (93.6–99.9)
Accuracy % (95% CI) 77.5 (73.9–81.2) 75.6 (68.0–83.2) 66.7 (60.2–73.1)
CI confidence interval
Kim et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2017) 25:61 Page 8 of 11
So far, only two previous studies have suggested a pre-
diction model for false-positive STEMI [9, 16]. Eduardo
et al.’s model only included somewhat static variables,
such as patient demographics, risk factors, and under-
lying disease, and the area under the curve showed mod-
erate predictive capacity (0.67) [9]. The risk score in
Tonga et al.’s study included dynamic variables, such as
chest pain and reciprocal change on ECG, similar to our
study, and revealed good predictability, with an area
under the curve of 0.88 [16]. We found that the ECG of
false-positive STEMI had several differences from true
STEMI: the height of the ST-elevation, location and
number of involved leads, and incidence of concave
morphology and reciprocal change. These ECG patterns
for false-positive STEMI are similar to those reported in
previous studies [8, 10], and concave morphology and
reciprocal change were independent risk factors in our
prediction model. STEMI is frequently accompanied by
reciprocal changes, which have been suggested to distin-
guish STEMI from other diseases [24, 25]. Reciprocal
change is also a surrogate marker for the severity of
STEMI [24, 26]. Our risk score model showed a good
ability to discriminate false-positive STEMI in the in-
ternal and external validation cohorts (AUROCs, 0.84
and 0.82, respectively). To our knowledge, this is the
first study that attempted to validate a prediction model
for false-positive STEMI with an external validation set.
Over the last decade, most EDs in tertiary hospitals have
tried to achieve the goal of early door-to-balloon time with
various strategies, such as a CP for primary PCI. However,
Barnes et al. suggested that during their study period, re-
duced door-to-balloon time was accompanied by increased
negative results of primary PCI [7]. Patients with false-
positive STEMI have been reported to have relatively poor
outcomes, because several foetal pathologic conditions
such as aortic dissection, pulmonary thromboembolism,
and cerebral haemorrhage that should be diagnosed with-
out delay can show ST elevation on ECG [11, 12, 19, 27].
This is the time to focus on how we can reduce the inci-
dence of negative primary PCI, rather than just speed up
the procedure. In recently published studies, further de-
creases in door-to-balloon time did not improve patient
mortality, suggesting that benefits from earlier PCI reached
a point of diminishing return [15]. Until now, the decision
of whether to perform primary PCI has depended on the
clinical physician’s individual capacity. Our prediction
model would help them make rapid decisions with better
rationale. However, when the cut-off value was applied, the
NPV of our risk model was 93.4%–96.7%, whereas the
PPV was 22.0–43.9%. We propose that if patients who
show ST elevation on ECG have a high score according to
our risk model, they should also be assessed for other aeti-
ologies. However, these assessments should be performed
promptly, and preparations should be made to ensure
immediate implementation of primary PCI in case of emer-
gency. The most appropriate assessment tool is point-of-
care ultrasonography, which has gradually become familiar
to emergency physicians and is widely used in the emer-
gency room [28]. Further research on the role of point-of-
care ultrasonography use by emergency physicians to rap-
idly determine false-positive STEMI should be performed.
Limitations
This study has several limitations. Firstly, it is possible
that there were patients with appropriate ST elevation
on ECG who died before CP activation. These patients
may have been more likely to have STEMI, so the inci-
dence of false-positive STEMI may have been reported
to be higher than it actually was. Secondly, most of the
patients who were included in this study are Koreans,
and it may be difficult to apply the results to inter-
national patients. Thirdly, there were only 202 patients
included in the external validation cohort, among which
only 22 patients had false-positive STEMI. These num-
bers were not sufficient to test the accuracy of the
model. Lastly, since our prediction model was analysed
only retrospectively, it is necessary to evaluate its pre-
dictive power in future prospective studies.
Conclusions
We presented a predictive model to help identify false-
positive STEMI patients early in the ED. Our model
should be investigated for accuracy through a more ex-
tensive validation study. Finally, prospective studies
should be performed to determine whether our model
will actually help reduce primary PCI for false-positive
STEMI in a real clinical environment.
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